GlassScriptPhysician profile
Laura Devita
NPI 1831532290
$9,082.81
in general payments reported to CMS, 2019-2025
25 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 77% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $1,065 · 2021: $766 · 2022: $621 · 2023: $2,179 · 2024: $1,832 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,748.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,985.75 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Spectra Wavewriter |
| Abbott Laboratories | $1,184.63 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $924.33 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Abbvie INC. | $481.97 | 2023-2025 | Qulipta, Ubrelvy |
| Vertos Medical, INC. | $474.90 | 2023-2024 | Mild Device Kit |
| Averitas Pharma INC. | $341.25 | 2023-2025 | Qutenza |
| Stryker Corporation | $328.69 | 2023-2024 | Omnicurve, Mild Device Kit, Multigen 2 |
| Medtronic USA, INC. | $326.96 | 2019-2020 | |
| Globus Medical, INC. | $153.90 | 2025 | Senza |
| Amgen INC. | $128.40 | 2019-2021 | |
| Tersera Therapeutics LLC | $116.10 | 2025 | Prialt |
| Avanos Medical | $102.32 | 2021 | |
| Spr Therapeutics, INC | $93.52 | 2024 | Sprint Pns System |
| Grt US Holding, INC. | $92.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $80.31 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $68.49 | 2022 | |
| Pfizer INC. | $35.75 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $34.46 | 2024-2025 | |
| Convatec INC. | $25.18 | 2024 | |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
| Bioventus LLC | $18.23 | 2024 | Durolane |
| Mml US, INC. | $16.91 | 2025 | Reactiv8 |
| Allergan, INC. | $16.00 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.95 | 2023 | Horizant |
| Scilex Pharmaceuticals INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Devita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.